Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal microbiota modulation refers to the deliberate alteration—through dietary changes, supplementation with probiotics/prebiotics, antibiotics, bacteriophage therapy, fecal microbiota transplantation, or other interventions—of the composition and/or activity of the complex microbial communities residing within the gastrointestinal tract. The goal is typically to restore balance (“eubiosis”) when dysbiosis has occurred due to disease states such as infections, inflammatory disorders, metabolic syndrome, neurodegenerative diseases like Alzheimer’s disease, and even psychological stress-related conditions. These interventions can influence a wide range of physiological processes including nutrient metabolism; maintenance and repair of the intestinal barrier; regulation/modulation of local and systemic immune responses; production/absorption/metabolism of key metabolites such as short-chain fatty acids; communication along the gut-brain axis; resistance against pathogen colonization; and overall host health outcomes. While not a single molecular target but rather an ecosystem-level intervention strategy affecting many molecular pathways simultaneously—and thus not considered a canonical therapeutic “target” like a receptor or enzyme—the concept is central to emerging therapies in gastroenterology and beyond.[1][2][3][4] **Note:** "Intestinal microbiota modulation" is not itself a molecule/receptor/therapeutic target but describes an intervention strategy aimed at altering an entire biological system. It does not fit standard definitions for drug targets such as receptors or enzymes.[1][2]
Restoration or alteration of microbial community composition and function through supplementation or transplantation; Enhancement of beneficial metabolite production by commensal bacteria; Suppression or displacement of pathogenic organisms via competitive exclusion or direct antagonism
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal microbiota modulation.